These nine companies are headed to Houston. Photo courtesy of TMC

Nine startups hailing from as far away as Sydney, Australia, are en route to Houston to participate in a week-long program at the Texas Medical Center's Innovation Factory.

The 2022 TMCi Accelerator for HealthTech Bootcamp is looking to accelerate these startups, which specialize in health tech innovation across the spectrum — maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

“One of the things I love about Bootcamp is the opportunity to showcase the diversity of innovation our ecosystem attracts," says Devin Dunn, head of the Accelerator for Healthtech, in a news release. "The breadth of clinical and operational expertise in our Medical Campus creates a unique learning ground, truly unmatched. Our tailored accelerator program allows for an experience that is personalized to each company’s stage, specialty and growth objectives.”

After the week at TMC, a smaller group of startups will be accepted into the TMCi Accelerator, a six-month program focused on maturing strategic relationships.

“Startup companies who are impacting the future of healthcare need clinical evidence to validate their value proposition and grow their businesses," says Emily Reiser, associate director of TMC Innovation, in the release. "Our platform at the TMC sources the best talent from around the world, performs rigorous diligence, and brings entrepreneurs together with our dedicated network to drive value for each stakeholder. We are seeing this value proposition resonate with entrepreneurs, including international companies preparing to enter the US market”

The nine startups that will be participating in the program, per the news release, include:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • Echo IQ, headquartered in Sydney, is a screening program that applies a proprietary algorithm to produce risk assessments for patients using their echocardiographic measurements.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.
Check out these conferences, pitch competitions, networking, and more in the month of August. Photo via Getty Images

10+ can't-miss Houston business and innovation events for August

where to be

Houstonians are transitioning into a new summer month, and the city's business community is mixing in networking and conference events with family vacations and time off. Here's a rundown of what all to throw on your calendar for August when it comes to innovation-related events.

This article will be updated as more business and tech events are announced.


August 1 — Beyond Bias: Essentials for an Equitable Community

During this seminar, Tracie Jae, Founder of The Quiet Rebel, will share a paradigm shift designed to disrupt the current DEI model.

Diversity, Equity, and Inclusion (DEI) is the accepted workforce best practice. As organizations continue to find the mix of techniques for their particular culture, we began to see the addition of other words like Belonging, Justice, and Access. Meanwhile, the impact appears the same - a focus on making space for “others” rather than actively creating a welcoming environment of mutual respect and acknowledgement. We have chosen to modify rather than innovate.

The event is Monday, August 1, 10 am to noon, at The Ion. Click here to register.

August 3 — Bayou Startup Showcase

The showcase features 24 companies from four accelerators: RED Labs, OwlSpark, RED Launch and BlueLaunch. You will be able to engage with these businesses, sign up for pre-orders, and buy products at their booths. Teams have recorded their pitches for you to learn about them in advance, watch during the event, or review afterward.

The event is Wednesday, August 3, 5 to 8 pm, at Saint Arnold Brewing Company. Click here to register.

August 4 — National Cancer Institute | SBIR Funding Opportunities

The TMCi Accelerator is excited to partner with the National Cancer Institute for a discussion about small business funding opportunities.

The event is Thursday, August 4, 1 to 3 pm, online. Click here to register.

August 8 — Intro to Finance Automation

Understand the benefits of finance automation and how to identify meaningful automation opportunities in your business. Learn from firsthand experiences of FinOptimal’s Founder & CEO, Jesse Rubenfeld.

The event is Monday, August 8, 10 am to noon, at The Ion. Click here to register.

August 11 — Illuminate Houston: An Innovation Conversation

Illuminate Houston is an event series highlighting business leaders who challenge the way we think about the future, featuring dynamic formats where speakers and attendees discuss trends, technologies, and issues that define how we do business. The Partnership welcomes Roberta L. Schwartz, Ph.D., Executive Vice President and Chief Innovation Officer of Houston Methodist on Thursday, August 11.

The event is Thursday, August 11, 1 to 2:30 pm, at Partnership Tower. Click here to register.

August 11 — Summer in the City: UH Students' Showcase Day

Throughout the "Summer in the City" class, students from the University of Houston Honors College have learned about creativity, leadership, entrepreneurship, and smart cities. Taking a mixed-media approach, and benefiting from guest lectures by Robert Cremins, Director of Creative Work: A Pre-Professional Program at UH, as well as panel discussions featuring entrepreneurs, innovators, and founder at the Ion, students have developed their design thinking and innovation skills and tackled problems experienced in Houston.

The event is Thursday, August 11, 5:30 to 7 pm, at the ion. Click here to register.

August 16 — Softeq Venture Studio Public Demo Day 

The Softeq Venture Studio invested $125,000 in cash and services in each of the fourteen early-stage startups to help them refine their business model, build their technology, and prepare them to scale. With 14 startups, the Q2 2022 cohort is the largest yet and brings the total portfolio to 27 companies. In this capstone event, founders have seven minutes each to present their pitch deck, demo their product, outline their ask, and answer questions.

The event is Tuesday, August 16, 5 to 7:30 pm, at The Ion. Click here to register.

August 16 — Enventure "Inspire" Seminar Series - Entrepreneurship

The "Inspire" Seminar Series was developed by Enventure to help students learn about the reality of working in the biotech and biomedical fields. The series consists of a number of events starring guest speakers coming from different areas in the biotech and biomedical industries. Dr. Lauren Cornell is an experienced research scientist with a strong history of military collaborations.

The event is Tuesday, August 16, 6 to 7:30 pm, online. Click here to register.

August 18 — Evolve Houston Relaunch Event

This past year, Evolve introduced a new logo and website to continue embarking on its mission to improve air quality and reduce greenhouse gas emissions through transportation electrification.

The event is Thursday, August 18, 8:30 am to 12:30 pm, at George R. Brown Convention Center. Click here to register.

August 18 — Transition on Tap

Transition On Tap is Greentown Labs' monthly networking event devoted to fostering conversations and connections among the climate and energy transition ecosystem in Houston and beyond. Entrepreneurs, investors, students, and friends of climatetech are invited to attend, meet colleagues, discuss solutions, and engage with our growing community. I

The event is Thursday, August 18, 5 to 7 pm, at Greentown Houston. Click here to register.

August 22 — Startup-Inside-a-Business 102: How to Find SIB Without Spending Any Money

Founders will learn how to look at their companies differently, to see how the capabilities and systems they’ve already created can be reconfigured to multiply growth, value, and valuation. Learn a step-by-step approach to finding the best potential startup inside and insights for estimating the potential value that’s waiting to be unlocked.

This workshop is the second in a series of three Startup-Inside-a-Business Workshops.

The event is Monday, August 22, 10 to 11:30 am, at The Ion. Click here to register.

August 29 — Startup-Inside-a-Business 103: Build One w/out Disrupting Existing Business

Founders will learn how getting investors involved early can end the need for founder cash investments while simultaneously establishing a higher company valuation. They’ll also learn how to manage the tradeoff between cost, risk, and reward by using proven techniques to gain proof before scaling up.

This workshop is the last in a series of three Startup-Inside-a-Business Workshops.

    The event is Monday, August 29, 10 to 11:30 am, at The Ion. Click here to register.

    Enrique Gomez joins the Houston Innovators Podcast to discuss Houston as an oncology innovation hub. Photo via TMC.edu

    How Houston is emerging as a leader for oncology innovation, according to this expert

    Houston innovators podcast episode 114

    Houston is currently establishing itself as a hub for health care innovation — and Enrique Gomez should know. He's worked in the field of biopharmaceuticals across the continent.

    As entrepreneur in residence at Texas Medical Center Innovation's Accelerator for Cancer Therapeutics, he works with early stage startups and researchers. However, for decades he's worked in a much later stage of drug development, holding leadership positions at Takada in Latin America and Shire in Boston.

    "Texas is very well recognized for cancer therapeutics," Gomez says on this week's episode of the Houston Innovators Podcast. "There's a lot of research going on. These researchers are looking at every angle — every possible strategy to tackle cancer."

    At ACT, Gomez connects the startups or instigators with the resources they need to get their life-saving solutions to market. With cancer, there's not one thing that's going to work. There have to be options for treating cancer.

    "Cancer is very heterogeneous. Not one strategy will be the single silver bullet to overcome the disease," Gomez says. "We are talking about personalized medicine. Every person is different and every cancer in every patient is different. It will require a number of approaches to overcome the health situation."

    Thankfully, through TMC's ACT and the numerous research institutions working on the future of oncology, Houston's a great spot to move that needle.

    "Houston is a place where everyone looks at when it comes to novel research and approaches to treating cancer," Gomez says. "The landscape here is going to be accelerated because we see much more collaboration between the founding institutions — and that's a very important element of growth. Houston has no comparison to any other place in terms of what's going on here and the level and quality of research."

    He shares more on how COVID-19 has affected drug development and research — as well as what's next for his own career — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

    Optellum, based in the TMC Innovation Institute, has entered into a partnership with Johnson & Johnson. Photo via Getty Images

    AI-optimized health startup with HQ in Houston takes its tech to the next level with new partner

    ending cancer

    Optellum, a startup whose technology helps doctors detect and treat lung cancer, has teamed up with one of the world's health care giants to broaden the software's reach.

    On August 18, Optellum — whose U.S. headquarters is at Houston's TMC Innovation Institute — unveiled its new collaboration with the Lung Care Initiative at Johnson & Johnson, which racked up global sales of $82.6 billion last year. Optellum's key contribution to the partnership is its AI-powered software that aids medical professionals in detecting and treating patients with lung cancer.

    With Optellum's AI-powered lung cancer diagnostics now being included in J&J's Lung Cancer Initiative, medical teams soon will enjoy access to an array of complementary technologies designed to improve diagnosis and treatment of early stage cancer. The Lung Cancer Initiative, launched in 2018 by J&J and Boston University, aims to prevent, detect, and cure lung cancer.

    Lung cancer ranks as the world's most common type of cancer and leading cause of cancer deaths. About 1.8 million people around the world die from lung cancer each year. The current five-year survival rate is just 20 percent, primarily due to most patients being diagnosed after the disease has reached an advanced stage.

    Optellum's Virtual Nodule Clinic software received clearance from the U.S. Food and Drug Administration (FDA) in March. Hospitals in the U.S. are rolling out the technology, with Asia-Pacific and European hospitals on track to eventually adopt the software.

    The Optellum platform identifies and tracks at-risk patients, and assigns a "lung cancer prediction" score to lung nodules — small lesions, frequently detected in chest CT scans, that may or may not be cancerous.

    "Optellum's vision is to redefine the early intervention of lung cancer by enabling every patient to be diagnosed and treated at the earliest possible stage, when the chances of cure are highest," the United Kingdom-based company says in a news release.

    The startup — a 2019 graduate of the Texas Medical Center's accelerator — hopes to apply the technology to other lung diseases, such as chronic obstructive pulmonary disease (COPD).

    Optellum recently was named one of the 101 best medical device startups in the United Kingdom. In June, the startup was among 38 AI projects chosen by the UK Department of Health and Social Care to participate in a roughly $50 million health care initiative.

    Václav Potěšil, founder and CEO of Optellum, says the Johnson & Johnson collaboration represents a "significant milestone" for his company.

    The J&J partnership "brings us one step closer to Optellum's vision of redefining early lung cancer treatment by helping every clinician in every hospital to make the right decisions and provide their patients the best chance to fight back," Potěšil says.

    Of the 35 people employed by Optellum, three are based in the U.S. and the rest in the United Kingdom. The company's team also includes several part-time consultants, most of whom are based in the U.S. By the end of this year, Optellum plans to expand its U.S. team with several full-time hires, including a senior executive located in Houston.

    Beginning next year in Houston, Optellum expects its technology to be available for patients in clinical settings.

    For Potěšil, Optellum's mission is personal. He lost an aunt to lung cancer within a year of her Stage 4 diagnosis.

    "I've seen firsthand how very healthy people can be killed, and it's still the most common and deadliest cancer worldwide," Potěšil is quoted as saying by the Texas Medical Center. "We are really focused on enabling cancer patients to be diagnosed at the earliest possible stage and be cured. It's not just the modeled data on the computer. It's addressing the right clinical problems to add value to doctors."

    Through a series B round and a federal grant, BiVACOR has raised $22 million in funding ahead of human trials. Photo via bivacor.com

    Houston-based artificial heart company snags $22M in fresh funds

    money moves

    Houston-based medtech company BiVACOR has picked up $22 million in funding — in the form of a series B round and a federal grant — to propel development of its Total Artificial Heart device for treatment of severe heart failure.

    In a May 19 news release, BiVACOR says it received a series B round of $19 million and a National Institutes of Health grant of $3 million. Boston-based Cormorant Asset Management and Australia's OneVentures, through its OneVentures Healthcare Fund III, led the round.

    OneVentures first invested in BiVACOR three years ago. According to Australia's Financial Review, OneVentures initially pumped $3 million (Australian dollars) into BiVACOR, with the potential of contributing as much as $10 million if BiVACOR met certain milestones. BiVACOR received a round of seed funding from U.S. investors in 2013.

    "BiVACOR's one-of-a-kind technology is supported by a remarkable team that has moved this technology a significant distance toward the clinic," Paul Kelly, managing partner of OneVentures, says in BiVACOR's news release.

    The fresh cash will support preparation for the first human trials of the device. As a short-term measure, the device can be implanted in someone awaiting a heart transplant. It's also designed to be a long-term alternative to a heart transplant.

    The BiVACOR device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

    "The commitment and interest from our investors validate our technology and the need for improved options to treat end-stage biventricular heart failure," says Daniel Timms, founder and CEO of BiVACOR. "With this financing, we will be able to expand our world-class team and undertake … verification activities so that we can commence our first-in-human early feasibility study in the near future."

    Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

    The company employs about a dozen people and says the funding will enable it to bring on another 10 employees.

    For 13 years, BiVACOR has been working on technology aimed at eliminating the need for heart transplants. Thus far, the BiVACOR device has been tested only on cows.

    "In heart failure, the heart becomes unable to pump enough blood to keep the body healthy and strong. At least 26 million people around the world are living with the disease, and the number is rising as populations age," IEEE Spectrumreported in 2019. "Patients with severe heart failure have a bleak outlook: Their best option is a heart transplant, but the limited number of donor hearts means that only about 5,000 patients around the world receive transplants each year. Thousands more patients are eligible for transplants, and some die while waiting for a donor organ."

    The Texas Medical Center's Innovation Institute named 15 Texas companies to its new cancer-focused accelerator program. Photo courtesy of TMCx

    TMC cancer therapeutic accelerator names inaugural cohort

    cancer innovation

    The Texas Medical Center named 15 groundbreaking researchers and companies to its inaugural class of the Accelerator for Cancer Therapeutics on Thursday. All hail from the Lone Star State.

    The ACT program is the only accelerator focused on cancer treatment at the earliest stages of commercialization, thanks to a $5 million grant from the Cancer Prevention and Research Institute of Texas awarded to the TMC in the fall of 2019.

    The nine-month program kicked-off at the end of January and will be run by TMC Innovation, according to a release from the TMC. It aims to provide the class with resources to help their oncology biotech projects reach new milestones, including even commercialization.

    The inaugural cohort is made up of companies and researchers exploring immunotherapy, cell therapy, targeted therapy, cancer pain, and drug platforms. The group is split about evenly between companies and academic researchers. The group of Texans includes:

    • Raptamer Discovery Group
    • IDA Therapeutics
    • Elbrus Therapeutics
    • Parthenon Therapeutics
    • Lokesh Battula
    • Aumeta
    • Autoimmunity Biologic Solutions
    • Max Mamonkin
    • Qing Yi
    • Astero Alta
    • TEZCAT Laboratories
    • Anil Sood
    • Coactigon
    • Xiadong Cheng
    • IonTx

    At the end of the nine months, the class will present an integrated strategic plan and at least one grant submission. They will also have the opportunity to pitch investors and corporations.

    The class will also gain support in grant writing, chemistry, and funding opportunities, as well as mentorship.

    "As the past year has shown, the pace of scientific discovery can be blistering," says Tom Luby, director of TMC Innovation. "At the same time, successfully translating research into effective therapies available to patients requires a mix of business, technical and regulatory skills that may not typically be available to researchers.

    "By linking the participants with mentors who can both advance their scientific work and support the technical needs, we expect this first class of ACT participants will make a meaningful difference for cancer patients in Texas and beyond."

    TMCx, which is also run by TMC Innovation, recently announced seven health tech companies that were selected to its 2021 class of its health tech accelerator.

    Broader in scope that the ACT accelerator, the TMCx startups focus on an array of subject matters from heart health to artificial intelligence to extremity rehabilitation.

    Ad Placement 300x100
    Ad Placement 300x600

    CultureMap Emails are Awesome

    7 lessons from a Houston-based unicorn startup founder

    taking notes

    At a fireside chat at SXSW, a Houston founder pulled back the curtain on his entrepreneurial journey that's taken him from an idea of how to make the chemicals industry more sustainable to a company valued at over $2 billion.

    Gaurab Chakrabarti, the CEO and co-founder of Solugen, joined the Greater Houston Partnership's Houston House at SXSW on Monday, March 13, for a discussion entitled, "Building a Tech Unicorn." In the conversation with Payal Patel, principal of Softeq Ventures, he share the trials and tribulations from the early days of founding Solugen. The company, which has raised over $600 million since its founding in 2016, has an innovative and carbon negative process of creating plant-derived substitutes for petroleum-based products.

    The event, which quickly reached capacity with eager SXSW attendees, allowed Chakrabarti to instill advice on several topics — from early customer acquisition and navigating VC investing to finding the right city to grow in and setting up a strong company culture.

    Here are seven pieces of startup advice from Chakrabarti's talk.

    1. Don’t be near a black hole.

    Chakrabarti began his discussion addressing the good luck he's had standing up Solugen. He's the first to admit that luck is an important element to his success, but he says, as a founder, you can set yourself up for luck in a handful of ways.

    “You do make your own luck, but you have to be putting in the work to do it," Chakrabarti says, adding that it's not an easy thing to accomplish. “There are things you can be doing to increase your luck surface area."

    One of the principals he notes on is not surrounding yourself with black holes. These are people who don't believe in your idea, or your ability to succeed, Chakrabarti explains, referencing a former dean who said he was wasting his talent on his idea for Solugen.

    2. The co-founder dynamic is the most important thing.

    Early on, Chakrabarti emphasizes how important having a strong co-founder relationship is, crediting Solugen's co-founder and CTO Sean Hunt for being his "intellectual ping-pong partner."

    “If you have a co-founder, that is the thing that’s going to make or break your company,” he says. “It’s not your idea, and it’s not your execution — it’s your relationship with your co-founder.”

    Hunt and Chakrabarti have been friends for 12 years, Chakrabarti says, and, that foundation and the fact that they've been passionate about their product since day one, has been integral for Solugen's success.

    "We had a conviction that we were building something that could be impactful to the rest of the world," he says.

    3. Confirm a market of customers early on.

    Chakrabarti says that in the early days of starting his company, he didn't have a concept of startup accelerators or other ways to access funding — he just knew he had to get customers to create revenue as soon as possible.

    He learned about the growing float spa industry, and how a huge cost for these businesses was peroxide that was used to sanitize the water in the floating pods. Chakrabarti and Hunt had created a small amount of what they were calling bioperoxide that they could sell at a cheaper cost to these spas and still pocket a profit.

    “We ended up owning 80 percent of the float spa market,” Chakrabarti says. “That taught us that, ‘wow, there’s something here.”

    While it was unglamourous work to call down Texas float spas, his efforts secured Solugen's first 100 or so customers and identified a path to profitability early on.

    “Find your niche market that allows you to justify that your technology or product that has a customer basis,” Chakrabarti says on the lesson he learned through this process.

    4. Find city-company fit.

    While Chakrabarti has lived in Houston most of his life, the reason Solugen is headquartered in Houston is not due to loyalty of his hometown.

    In fact, Chakrabarti shared a story of how a potential seed investor asked Chakrabarti and Hunt to move their company to the Bay Area, and the co-founders refused the offer and the investment.

    “There’s no way our business could succeed in the Bay Area," Chakrabarti says. He and Hunt firmly believed this at the time — and still do.

    “For our business, if you look at the density of chemical engineers, the density of our potential customers, and the density of people who know how to do enzyme engineering, Houston happened to be that perfect trifecta for us," he explains.

    He argues that every company — software, hardware, etc. — has an opportunity to find their ideal city-company fit, something that's important to its success.

    5. Prove your ability to execute.

    When asked about pivots, Chakrabarti told a little-known story of how Solugen started a commercial cleaning brand. The product line was called Ode to Clean, and it was marketed as eco-friendly peroxide wipes. At the time, Solugen was just three employees, and the scrappy team was fulfilling orders and figuring out consumer marketing for the first time.

    He says his network was laughing at the idea of Chakrabarti creating this direct-to-consumer cleaning product, and it was funny to him too, but the sales told another story.

    At launch, they sold out $1 million of inventory in one week. But that wasn't it.

    “Within three months, we got three acquisition offers," Chakrabarti says.

    The move led to a brand acquisition of the product line, with the acquirer being the nation's largest cleaning wipe provider. It meant three years of predictable revenue that de-risked the business for new investors — which were now knocking on Solugen's door with their own investment term sheets.

    “It told the market more about us as a company,” he says. “It taught the market that Solugen is a company that is going to survive no matter what. … And we’re a team that can execute.”

    What started as a silly idea led to Solugen being one step closer to accomplishing its long-term goals.

    “That pivot was one of the most important pivots in the company’s history that accelerated our company’s trajectory by four or five years," Chakrabarti says.

    6. Adopt and maintain a miso-management style.

    There's one lesson Chakrabarti says he learned the hard way, and that was how to manage his company's growing team. He shares that he "let go of the reins a bit" at the company's $400-$500 million point. He says that, while there's this idea that successful business leaders can hire the best talent that allows them to step back from the day-to-day responsibilities, that was not the right move for him.

    “Only founders really understand the pain points of the business," Chakrabarti says. "Because it’s emotionally tied to you, you actually feel it."

    Rather than a micro or macro-management style, Chakrabarti's describes his leadership as meso-management — something in between.

    The only difference, Chakrabarti says, is how he manages his board. For that group, he micromanages to ensure that they are doing what's best for his vision for Solugen.

    7. Your culture should be polarizing.

    Chakrabarti wrapped up his story on talking about hiring and setting up a company culture for Solugen. The company's atmosphere is not for everyone, he explains.

    “If you’re not polarizing some people, it’s not a culture,” Chakrabarti says, encouraging founders to create a culture that's not one size fits all.

    He says he was attracted to early employees who got mad at the same things he did — that passion is what makes his team different from others.

    Houston tech company to acquire IT infrastructure startup

    M&A moves

    Hewlett Packard Enterprise has announced its plans to acquire a San Jose, California-based startup.

    HPE, which relocated its headquarters to Houston from the Bay Area a couple years ago, has agreed to acquire OpsRamp, a software-as-a-service company with an IT operations management, or ITOM, platform that can monitor, automate, and manage IT infrastructure, cloud resources, and more.

    According to a news release from HPE, the OpsRamp platform will be merged with the HPE GreenLake edge-to-cloud platform, which supports more than 65,000 customers, powers over two million connected devices, and manages more than one exabyte of data with customers worldwide.

    The new integrated system "will reduce the operational complexity of multi-vendor and multi-cloud IT environments that are in the public cloud, colocations, and on-premises," per the statement.

    “Customers today are managing several different cloud environments, with different IT operational models and tools, which dramatically increases the cost and complexity of digital operations management,” says HPE's CTO Fidelma Russo in the release. “The combination of OpsRamp and HPE will remove these barriers by providing customers with an integrated edge-to-cloud platform that can more effectively manage and transform multi-vendor and multi-cloud IT estates.

    "This acquisition advances HPE hybrid cloud leadership and expands the reach of the HPE GreenLake platform into IT Operations Management,” she continues.

    HPE's corporate venture arm, Pathfinder, invested in OpsRamp in 2020. The company raised $57.5 million prior to the acquisition. Other investors included Morgan Stanley Expansion Capital and Sapphire Ventures, per TechCrunch.

    “The integration of OpsRamp’s hybrid digital operations management solution with the HPE GreenLake platform will provide an unmatched offering for organizations seeking to innovate and thrive in a complex, multi-cloud world. Partners and the channel will also play a pivotal role to advance their as-a-service offerings, as enterprises look for a unified approach to better manage their operations from the edge to the cloud,” says Varma Kunaparaju, CEO of OpsRamp, in the release.

    “We look forward to leveraging the scale and reach of HPE’s global go-to-market engine to deliver our unique offering and are excited for this journey ahead as part of HPE.”

    3 Houston innovators to know this week

    Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space tech to software development — recently making headlines in Houston innovation.


    Michael Suffredini, CEO and president of Axiom Space

    Axiom's CEO announced a new mission and space suit design. Photo courtesy of Axiom Space

    It was a big news week for Axiom Space. The Houston company announced its next commercial space mission with NASA to the International Space Station a day before it unveiled its newly design space suit that will be donned by the astronauts headed to the moon.

    “We’re carrying on NASA’s legacy by designing an advanced spacesuit that will allow astronauts to operate safely and effectively on the Moon,” says Micahel Suffredini, CEO of Axiom, in a statement. “Axiom Space’s Artemis III spacesuit will be ready to meet the complex challenges of the lunar south pole and help grow our understanding of the Moon in order to enable a long-term presence there.”

    Called the Axiom Extravehicular Mobility Unit, or AxEMU, the prototype was revealed at Space Center Houston’s Moon 2 Mars Festival on March 15. According to Axiom, a full fleet of training spacesuits will be delivered to NASA by late this summer. Read more.

    Julie King, president of NB Realty Partners

    Houston's access to lab space continues to be a challenge for biotech companies. Photo via Getty Images

    In terms of Houston developing as an attractive hub for biotech companies, Julie King says the city still has one major obstacle: Available lab space.

    She writes in a guest column for InnovationMap that biotech startups need specialized space that can hold the right equipment. That's not cheap, and it's usually a challenge for newer companies to incur that cost.

    "However, with realistic expectations about these challenges, the good news is that once settled into a facility that is a fit, Houston’s emerging biotech companies can thrive and grow," she writes. Read more.

    Owen Goode, executive vice president at Zaelot

    Houston software development firm Axon is planning its Texas expansion thanks to its recent acquisition. Photo via LinkedIn

    Owen Goode is a huge fan of Houston. That's why when his software design firm, Axon, got acquired by Zaelot, led by CEO Jeff Lombard, in January, he made sure the deal would mean growth in the region.

    Zaelot is a global, software firm with a presence in 14 countries, mostly focused in the United States, Uruguay, and Iceland. With the acquisition of Axon, the combined company is poised to expand in Texas, beginning in Houston, Goode says.

    “Together we have a strong suite of offerings across a wide variety of domains including full-stack development, cloud/data engineering, design, staff augmentation, project management, and software architecture. We also have experience in multiple domains, including health care, aviation, defense, finance, and startups,” says Goode. Read more.